Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …
J Rodríguez-Carrio, A Burska, PG Conaghan… - RMD open, 2023 - rmdopen.bmj.com
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
[PDF][PDF] Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review …
J Rodríguez Carrio, A Burska, PG Conaghan - RMD Open, 2023 - digibuo.uniovi.es
ABSTRACT Background Type I interferons (IFN-I) contribute to a broad range of rheumatic
and musculoskeletal diseases (RMDs). Compelling evidence suggests that the …
and musculoskeletal diseases (RMDs). Compelling evidence suggests that the …
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …
J Rodríguez-Carrio, A Burska, PG Conaghan… - RMD …, 2023 - research.nu.edu.kz
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …
J Rodríguez-Carrio, A Burska, PG Conaghan… - RMD …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …
J Rodriguez-Carrio, A Burska, PG Conaghan, WA Dik… - RMD Open, 2023 - diva-portal.org
ABSTRACT Background Type I interferons (IFN-I) contribute to a broad range of rheumatic
and musculoskeletal diseases (RMDs). Compelling evidence suggests that the …
and musculoskeletal diseases (RMDs). Compelling evidence suggests that the …
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …
J Rodríguez-Carrio, A Burska, PG Conaghan, WA Dik… - 2023 - bora.uib.no
Background: Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …
J Rodríguez-Carrio, A Burska, PG Conaghan, WA Dik… - RMD Open, 2023 - europepmc.org
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …
J Rodríguez-Carrio, A Burska, PG Conaghan… - RMD …, 2023 - eprints.whiterose.ac.uk
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …
J Rodriguez-Carrio, A Burska, PG Conaghan, WA Dik… - RMD Open, 2023 - swepub.kb.se
BackgroundType I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
[HTML][HTML] Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review …
J Rodríguez-Carrio, A Burska, PG Conaghan, WA Dik… - RMD …, 2023 - ncbi.nlm.nih.gov
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …